Menu Search
Equities

EyePoint Pharmaceuticals Inc

PV3B:BER

EyePoint Pharmaceuticals Inc

Actions
  • Price (EUR)8.11
  • Today's Change-0.23 / -2.76%
  • Shares traded--
  • 1 Year change+0.15%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 14:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year EyePoint Pharmaceuticals Inc grew revenues 11.14% from 41.40m to 46.02m while net income improved from a loss of 102.25m to a smaller loss of 70.80m.
Gross margin91.35%
Net profit margin-172.29%
Operating margin-195.71%
Return on assets-34.74%
Return on equity-60.81%
Return on investment-47.07%
More ▼

Cash flow in USDView more

In 2023, EyePoint Pharmaceuticals Inc increased its cash reserves by 193.80%, or 185.63m. Cash Flow from Financing totalled 187.07m or 406.51% of revenues. In addition the company generated 1.88m in cash from operations while cash used for investing totalled 3.32m.
Cash flow per share-1.84
Price/Cash flow per share--
Book value per share4.38
Tangible book value per share4.38
More ▼

Balance sheet in USDView more

EyePoint Pharmaceuticals Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 281.26m.
Current ratio4.75
Quick ratio4.69
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.